MOTS-c vs Cagrilintide

MOTS-c and Cagrilintide represent two distinct classes of research peptides with convergent interest in metabolic regulation but fundamentally different origins and mechanisms. MOTS-c, a mitochondrial-derived peptide, operates as an endogenous metabolic signal with preclinical evidence supporting roles in insulin sensitivity and exercise enhancement. Cagrilintide, a synthetic amylin analog developed by Novo Nordisk, targets satiety pathways and has advanced through Phase 3 clinical trials in combination with semaglutide. This comparison dissects their unique mechanisms, evidence bases, dosing protocols, and safety profiles to clarify their respective niches in metabolic research.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene (MT-RNR1), first characterized in 2015 by Lee et al. at the University of Southern California. It functions as a metabolic regulator primarily through AMPK activation, a key energy-sensing kinase. In preclinical mouse models, MOTS-c administration prevented diet-induced obesity and insulin resistance, enhanced exercise capacity—with aged mice running twice as long on treadmill tests—and mitigated age-related metabolic decline. A modified analog, CB4211, demonstrated good tolerability in a Phase 1 human trial, though no clinical trials of the native MOTS-c peptide have been completed. Research suggests its effects are mediated through mitochondrial-nuclear communication, positioning it as a potential exercise mimetic and anti-aging agent.

Cagrilintide is a long-acting synthetic analog of human amylin, a pancreatic hormone co-secreted with insulin that regulates satiety via hindbrain pathways. Developed by Novo Nordisk, it is studied both as a standalone therapy and in a fixed-dose combination with semaglutide (CagriSema). The CagriSema strategy targets complementary appetite circuits: amylin acts on the area postrema and nucleus tractus solitarius, while GLP-1 engages hypothalamic and gut-mediated signals. In the REDEFINE Phase 3 program, CagriSema achieved a mean weight loss of 20.4% at 68 weeks, surpassing semaglutide alone. Novo Nordisk filed for FDA approval in 2026, reflecting robust clinical evidence. Standalone cagrilintide also shows significant weight reduction, though less pronounced than the combination.

Both MOTS-c and Cagrilintide are investigated for metabolic health, particularly in contexts of energy balance and glucose regulation. However, their research trajectories diverge: MOTS-c is additionally explored for anti-aging applications, leveraging its mitochondrial signaling to counteract age-related metabolic decline and enhance physical performance. In contrast, Cagrilintide is predominantly studied for weight management, with its amylin-based mechanism directly targeting appetite suppression and caloric intake reduction. This distinction reflects their different evidence stages—MOTS-c remains largely preclinical, while Cagrilintide has advanced to late-stage clinical trials—shaping the experimental questions each peptide can address.

MOTS-c: In preclinical animal studies, no adverse effects have been reported, but human tolerability for the native peptide remains completely unknown due to the absence of completed clinical trials. The modified analog CB4211 showed good tolerability in a Phase 1 trial, offering preliminary safety signals. Researchers should exercise caution, as mitochondrial-targeted peptides may have unanticipated off-target effects. Cagrilintide: In clinical trials, gastrointestinal adverse events occurred in 79.6% of the CagriSema group versus 39.9% with placebo, including nausea, vomiting, diarrhea, and constipation. These events were mainly transient and mild-to-moderate. Safety concerns mirror the GLP-1 class, including potential risks of pancreatitis, gallbladder events, and thyroid C-cell tumors observed in rodent studies, warranting careful monitoring in long-term research.